Attorney Docket No.: 3985.240-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Havelund et al.

Application No.: 09/398,365

Group Art Unit: 1656

Filed: September 17, 1999

Examiner: J. Siew

Confirmation No: 9987

For: Acylated Insulin

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Supplemental Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

1. <u>1</u>. 11 (1. 11)

The Committee of the House

Attorney Docket No. 3985,240-US

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The supplemental information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: October 8, 2003

Richard W. Bork, Reg. No. 36,459 Novo Nordisk Pharmaceuticals, Inc. 100 College Road West Princeton, NJ 08540

(609) 987-5800

CEPTON SAY PERSON

23650

FORM PTO-1449 (Rev. 2 32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Atty. Docket No. 3985,24	40 US	Serial No. 09/3	98,365	
			Applicant Havelund et al.				
(Use several sheets if necessary)			Fung Date September 17, 1999		Group 1656		
		U.S. PATE	ENT DOCUMENTS				
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		G DATE ROPRLATE
	5,6 93,609	12-2-97 I	Baker et al.				
	5,922,675	7-13 - 99	Baker et al.				
	2001/0041786	11-15-01	Brader et al.				<u>.</u>
		FOREIGN PA	TENT DOCUMENTS	" " 1			
	DOCUMENT					TRANS	LATION
-	NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
- ·							_
			· · · · · · · · · · · · · · · · · · ·				
					<u></u> _		
	OTHER D	OCUMENTS (Including	Author, Title, Date, Pertin	ent Pages, Etc.			
						•	
•					-		
			· · · · · · · · · · · · · · · · · · ·				
			<u> </u>				
	_		·		 .		
					· · · · · · · · · · · · · · · · · · ·	···	